Norum Jan
Department of Oncology, PO Box 13, University Hospital of North Norway, N-9038 Tromsø, Norway.
Expert Opin Pharmacother. 2006 Aug;7(12):1617-25. doi: 10.1517/14656566.7.12.1617.
Trastuzumab has shown activity in patients with early breast cancer that overexpresses HER-2, and this drug has been employed in the adjuvant setting. Significant resources have been allocated to finance this new therapy. To support decision makers in their allocation of resources, cost-effectiveness models are constructed to compare the costs and outcomes of anticancer therapy. This survey focuses on studies exploring adjuvant trastuzumab therapy in early-stage breast cancer that have been published since 2003, which report on efficacy, benefit and/or cost data in this setting. The paper summarises the results, focuses on the level of evidence of these studies, compares the calculated cost-effectiveness ratios and makes recommendations for future cost-effectiveness analyses.
曲妥珠单抗已在HER-2过表达的早期乳腺癌患者中显示出活性，并且该药物已用于辅助治疗。大量资源已被分配用于资助这种新疗法。为了帮助决策者进行资源分配，构建了成本效益模型以比较抗癌治疗的成本和结果。本次调查聚焦于自2003年以来发表的探索早期乳腺癌辅助曲妥珠单抗治疗的研究，这些研究报告了该治疗环境下的疗效、益处和/或成本数据。本文总结了结果，关注这些研究的证据水平，比较了计算出的成本效益比，并对未来的成本效益分析提出了建议。
